SavedAdd your journal

Journals / Turkish Journal of Gastroenterology / 2018 / Cilt: 29 - Sayı: 1

Liver fibrosis

M. Merve AYDIN
KAMİL CAN AKÇALI
Pages
14–21
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, important antifibrotic therapeutic approaches and experimental liver fibrosis models will be discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Liver fibrosis is a wound-healing response generated against an insult to the liver that causes liver injury.
📊
Key Findings & Data:It has the potential to progress into cirrhosis, and if not prevented, it may lead to liver cancer and liver failure.
💡
Conclusion & Impact:In addition, important antifibrotic therapeutic approaches and experimental liver fibrosis models will be discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Liver fibrosis is a wound-healing response generated against an insult to the liver that causes liver injury. It has the potential to progress into cirrhosis, and if not prevented, it may lead to liver cancer and liver failure. The activation of hepatic stellate cells (HSCs) is the central event underlying liver fibrosis. In addition to HSCs, numerous studies have supported the potential contribution of bone marrow-derived cells and myofibroblasts to liver fibrosis. The liver is a heterogeneous organ; thus, molecular and cellular events that underlie liver fibro-genesis are complex. This review aims to focus on major events that occur during liver fibrogenesis. In addition, important antifibrotic therapeutic approaches and experimental liver fibrosis models will be discussed.

🔖

Cite This Article

AYDIN, M. M., AKÇALI, K. C. (2018). Liver fibrosis. Turkish Journal of Gastroenterology, Cilt: 29 - Sayı: 1, 14–21. https://ajindex.com/articles/410088

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Bansal R, Nagórniewicz B, Prakash J. Clinical advancements in the targeted therapies against liver fibrosis. Mediators Inflamm 2016
  2. 7629724. [CrossRef] 89. Lipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the pro-cess of fibrosis. Fibrogenesis Tissue Repair 2012
  3. S24. [CrossRef] 88. Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, Schup-pan D. Inhibition of integrin alpha beta on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fi-brosis progression. Gastroenterology 2008
  4. [CrossRef] 87. McCaffrey AP, Nakai H, Pandey K, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003
  5. [CrossRef] 86. Chisari FV, Filippi P, McLachlan A, et al. Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol 1986
  6. Larter CZ, Yeh MM, Haigh WG, et al. Dietary modification damp-ens liver inflammation and fibrosis in obesity-related fatty liver dis-ease. Obesity (Silver Spring) 2013
  7. [CrossRef] 84. Mauad TH, van Nieuwkerk CM, Dingemans KP, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangi-tis and hepatocarcinogenesis. Am J Pathol 1994
  8. Fickert P, Fuchsbichler A, Wagner M, et al. Regurgitation of bile ac-ids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterol 2004
  9. [CrossRef] 82. Larter CZ, Yeh MM. Animal models of NASH: getting both pathol-ogy and metabolic context right. J Gastroenterol Hepatol 2008
  10. [CrossRef] 81. Hayashi H, Sakai T. Animal models for the study of liver fibrosis: new insights from knockout mouse models. Am J Physiol Gastroin-test Liver Physiol 2011
  11. G729-38. [CrossRef] 80. Park KC, Park JH, Jeon JY, et al. A new histone deacetylase inhib-itor improves liver fibrosis in BDL rats through suppression of hepatic stellate cells. Br J Pharmacol 2014
  12. [CrossRef] 79. Rodríguez-Garay EA, Agüero RM, Pisani G, Trbojevich RA, Farroni A, Viglianco RA. Rat model of mild stenosis of the common bile duct. Res Exp Med (Berl) 1996
  13. [CrossRef] 78. Denda A, Kitayama W, Kishida H, et al. Development of hepa-tocellular adenomas and carcinomas associated with fibrosis in C57BL/6J